CONKO-001 evaluated the role of adjuvant gemcitabine after curative-intent resection for pancreatic cancer. The study became an important reference point because recurrence after apparently successful pancreatic surgery is common, reflecting both local and systemic microscopic disease. Long-term follow-up showed a clear improvement in disease-free survival with adjuvant gemcitabine compared with observation. The study helped establish postoperative systemic therapy as an essential part of management after pancreatic resection rather than viewing surgery as definitive treatment on its own. For surgeons, the key implication is that the quality of resection and postoperative recovery must be aligned with timely access to systemic therapy. Pancreaticoduodenectomy and other pancreatic operations carry substantial physiological stress, so nutritional optimization, complication prevention and coordinated postoperative care can directly affect whether patients are able to proceed with adjuvant treatment. CONKO-001 also illustrates the importance of long-term follow-up in surgical oncology. Early perioperative success does not capture the real therapeutic objective when recurrence remains common. Modern pancreatic cancer care therefore integrates surgery, pathology, systemic therapy, imaging and multidisciplinary review from the outset, with the resection serving as one critical step in a longer oncological pathway.